Although the advent of retinal ablation and intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs have improved the prognosis in threshold and prethreshold ROP, some treated eyes still experience retinal detachment (3, 4). This evidence concerns the gene VEGFA and retinal detachment.